Search

Your search keyword '"Lokhorst, A. M."' showing total 982 results

Search Constraints

Start Over You searched for: Author "Lokhorst, A. M." Remove constraint Author: "Lokhorst, A. M."
982 results on '"Lokhorst, A. M."'

Search Results

1. First Results from the Dragonfly Ultrawide Survey: the Largest Eleven Quenched Diffuse Dwarf Galaxies in 3100 deg$^2$ with Spectroscopic Confirmation

2. Realizing the potential of the Dragonfly Spectral Line Mapper: Calibration methods and on-sky performance

3. The Dragonfly Spectral Line Mapper: Completion of the 120-lens array

4. The Dragonfly Spectral Line Mapper: Design and First Light

5. The pathfinder Dragonfly Spectral Line Mapper: Pushing the limits for ultra-low surface brightness spectroscopy

6. Distributed Aperture Telescopes and the Dragonfly Telephoto Array

7. Wide-field ultra-narrow-bandpass imaging with the Dragonfly Telephoto Array

12. Responsiveness of the condition-specific Outcome measures for VAscular MAlformations (OVAMA) questionnaire to measure symptoms and appearance in patients with vascular malformations.

13. Bortezomib before and after high‐dose therapy in transplant‐eligible patients with newly diagnosed multiple myeloma: Long‐term overall survival after more than 10 years of follow‐up from the phase III HOVON‐65/GMMG‐HD4 trial

14. Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma:Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial

15. Genetic mutations and phenotype characteristics in peripheral vascular malformations: A systematic review.

16. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial

23. Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

24. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

31. Safety and effectiveness of surgical excision of medium, large, and giant congenital melanocytic nevi:A systematic review and meta-analysis

32. Supplementary Figure 1 from T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells

33. Supplementary Figure 2 from T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells

34. Data from T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells

37. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

41. Supplementary Figure Legends from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance

42. Supplementary Data from Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells

44. Supplementary Figure 3 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

45. Supplementary Figure 2 from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance

46. Supplementary Figure 3 from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance

47. Supplementary Figure 1 from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance

48. Supplementary Figure 4 from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance

49. Supplemental Data from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

Catalog

Books, media, physical & digital resources